-

JBTM Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into JBTM (JBTM)

JBT Marel management told investors on May 5, 2026 that Prepared Food and Beverage margins would be up year-over-year and improve sequentially through 2026. Second-quarter results disclosed logistics constraints and production inefficiencies in that same segment, and the stock fell roughly 7.9%.

NEW YORK--(BUSINESS WIRE)--Shareholders of JBT Marel Corporation (NYSE: JBTM) absorbed a decline of approximately 7.9% after second-quarter adjusted EPS of $1.95 came in below the $2.02 consensus estimate, alongside disclosed logistics constraints and production inefficiencies in the Prepared Food and Beverage segment. If you lost money on JBTM shares, you are encouraged to submit your information for a free case evaluation. You may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500.

On the Company's May 5, 2026 first-quarter earnings call, Chief Financial Officer Matthew Meister stated: "Margins will be up year-over-year in Prepared Food and Beverage. That is our forecast for that segment, yes." Meister added that the Company "should see sequential improvement going forward from Q1 all the way through the year" and that he "would expect to continue to see significant progress in Q2."

On the same call, Chief Executive Officer Brian Deck stated that "our teams are executing well despite the dynamic macro environment." Management also said it remained "confident in delivering our original earnings guidance for the year." Second-quarter results instead disclosed delayed revenue and pressured performance in Prepared Food and Beverage, margin friction, and a non-cash impairment charge. Adjusted EPS came in $0.07 below consensus.

JBTM investors who suffered losses may request an evaluation of their legal rights here or call Joseph E. Levi, Esq. at (212) 363-7500.

WHY LEVI & KORSINSKY -- Ranked in ISS Securities Class Action Services' Top 50 Report for seven consecutive years, Levi & Korsinsky, LLP is a nationally recognized leader in shareholder rights litigation. With a team of over 70 professionals, the firm has recovered hundreds of millions of dollars for investors.

Frequently Asked Questions About the JBTM Investigation

Q: Which statements are being investigated as potentially misleading? A: The investigation concerns whether JBTM Corporation made materially false or misleading statements regarding expected margin recovery and sequential improvement in its Prepared Food and Beverage segment. Second-quarter results instead disclosed logistics constraints and production inefficiencies in that segment, and the stock declined approximately 7.9%.

Q: How much did JBTM stock drop? A: Shares fell approximately 7.9% after the Company reported second-quarter adjusted EPS of $1.95 versus the $2.02 consensus estimate, together with disclosed segment execution issues and a non-cash impairment charge. Investors who purchased shares and suffered losses may be eligible to seek recovery.

Q: Who is eligible to participate in the JBTM investigation? A: Investors who purchased JBTM stock or securities and suffered financial losses may be eligible. Eligibility is based on purchase date and documented losses -- not on whether you still hold the shares.

Q: What do JBTM investors need to do right now? A: Gather brokerage records including purchase dates, share quantities, and prices paid. Contact Levi & Korsinsky for a free, no-obligation evaluation at jlevi@levikorsinsky.com or (212) 363-7500. No immediate action is required to remain eligible to participate in the investigation.

Q: What documents do I need to participate? A: Brokerage statements or trade confirmations showing purchase dates, share quantities, prices paid, and any subsequent sale dates and prices.

Q: What if I already sold my JBTM shares -- can I still recover losses? A: Yes. Eligibility is based on when you purchased, not whether you still hold the shares. Investors who bought JBTM and sold at a loss may still participate in the investigation.

Q: What does it cost me to participate? A: There is no upfront cost to participate. Securities investigations and any resulting actions are generally handled on a contingency basis. No upfront fees, no retainer, and no out-of-pocket costs.

Q: Do I need to go to court or give testimony? A: No. Participating in the investigation does not require court appearances or depositions.

Attorney Advertising. Prior results do not guarantee similar outcomes.

Contacts

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171

Levi & Korsinsky, LLP

NYSE:JBTM

Release Versions

Contacts

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171

More News From Levi & Korsinsky, LLP

EXEL Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Exelixis (EXEL)

NEW YORK--(BUSINESS WIRE)--Exelixis (NASDAQ: EXEL) shares dropped in after-hours trading after the Company reported Q2 revenue of approximately $628.7 million, missing consensus estimates, and lowered and narrowed its full-year 2026 revenue outlook. If you suffered a loss on your Exelixis investment, you are encouraged to submit your information here. You may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500. The revenue shortfall came alon...

LZ Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into LegalZoom.com, Inc. (LZ)

NEW YORK--(BUSINESS WIRE)--LegalZoom.com, Inc. (NASDAQ: LZ) shares dropped after the Company's August 5 second-quarter release, in which adjusted earnings per share came in at $0.16 versus the $0.15 consensus -- while full-year revenue guidance was reduced to approximately $795 million to $805 million from $810 million to $830 million. If you lost money on LZ shares, click here to submit your information. You may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telep...

EBS Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Emergent BioSolutions (EBS)

NEW YORK--(BUSINESS WIRE)--Emergent BioSolutions (NYSE: EBS) shareholders took losses after the Company disclosed a $191.3 million non-cash impairment on its NARCAN franchise, attributed to increased competition and pricing pressure in naloxone. If you suffered a loss on your Emergent BioSolutions investment, you are encouraged to click here to submit your information. You may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500. NARCAN Nasal...
Back to Newsroom